These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

470 related articles for article (PubMed ID: 21848364)

  • 41. Inhibitors of Deubiquitinating Enzymes Block HIV-1 Replication and Augment the Presentation of Gag-Derived MHC-I Epitopes.
    Setz C; Friedrich M; Rauch P; Fraedrich K; Matthaei A; Traxdorf M; Schubert U
    Viruses; 2017 Aug; 9(8):. PubMed ID: 28805676
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [The action of TSG101 on HIV-1 budding and related inhibitors].
    Chen HF; Liu XY
    Yao Xue Xue Bao; 2008 Dec; 43(12):1165-70. PubMed ID: 19244744
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Human Immunodeficiency Virus Gag and protease: partners in resistance.
    Fun A; Wensing AM; Verheyen J; Nijhuis M
    Retrovirology; 2012 Aug; 9():63. PubMed ID: 22867298
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Genetic determinants in HIV-1 Gag and Env V3 are related to viral response to combination antiretroviral therapy with a protease inhibitor.
    Ho SK; Perez EE; Rose SL; Coman RM; Lowe AC; Hou W; Ma C; Lawrence RM; Dunn BM; Sleasman JW; Goodenow MM
    AIDS; 2009 Aug; 23(13):1631-40. PubMed ID: 19625947
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Conserved Interaction of Lentiviral Vif Molecules with HIV-1 Gag and Differential Effects of Species-Specific Vif on Virus Production.
    Zheng W; Ling L; Li Z; Wang H; Rui Y; Gao W; Wang S; Su X; Wei W; Yu XF
    J Virol; 2017 Apr; 91(7):. PubMed ID: 28122978
    [TBL] [Abstract][Full Text] [Related]  

  • 46. New approaches for antiviral targeting of HIV assembly.
    Prevelige PE
    J Mol Biol; 2011 Jul; 410(4):634-40. PubMed ID: 21762804
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Structural and functional insights into the HIV-1 maturation inhibitor binding pocket.
    Waki K; Durell SR; Soheilian F; Nagashima K; Butler SL; Freed EO
    PLoS Pathog; 2012; 8(11):e1002997. PubMed ID: 23144615
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Natural-product-library-based screening for discovery of capsid C-terminal domain targeted HIV-1 inhibitors.
    Zhang DW; Luo RH; Xu L; Yang LM; Xu XS; Zheng YT; Luo H
    Int J Antimicrob Agents; 2020 Apr; 55(4):105926. PubMed ID: 32092396
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Activity of the small modified amino acid alpha-hydroxy glycineamide on in vitro and in vivo human immunodeficiency virus type 1 capsid assembly and infectivity.
    Abdurahman S; Végvári A; Youssefi M; Levi M; Höglund S; Andersson E; Horal P; Svennerholm B; Balzarini J; Vahlne A
    Antimicrob Agents Chemother; 2008 Oct; 52(10):3737-44. PubMed ID: 18644965
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A broad spectrum anti-HIV inhibitor significantly disturbs V1/V2 domain rearrangements of HIV-1 gp120 and inhibits virus entry.
    Berinyuy E; Soliman ME
    J Recept Signal Transduct Res; 2016; 36(2):119-29. PubMed ID: 26446906
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Targeting protein-protein interactions: a promising avenue of anti-HIV drug discovery.
    Zhan P; Li W; Chen H; Liu X
    Curr Med Chem; 2010; 17(29):3393-409. PubMed ID: 20712566
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The Myxobacterial Metabolite Soraphen A Inhibits HIV-1 by Reducing Virus Production and Altering Virion Composition.
    Fleta-Soriano E; Smutná K; Martínez JP; Lorca Oró C; Sadiq SK; Mirambeau G; Lopez-Iglesias C; Bosch M; Pol A; Brönstrup M; Diez J; Meyerhans A
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28533249
    [TBL] [Abstract][Full Text] [Related]  

  • 53. HIV-1 gag: an emerging target for antiretroviral therapy.
    Tedbury PR; Freed EO
    Curr Top Microbiol Immunol; 2015; 389():171-201. PubMed ID: 25731773
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Identification of a Structural Element in HIV-1 Gag Required for Virus Particle Assembly and Maturation.
    Novikova M; Adams LJ; Fontana J; Gres AT; Balasubramaniam M; Winkler DC; Kudchodkar SB; Soheilian F; Sarafianos SG; Steven AC; Freed EO
    mBio; 2018 Oct; 9(5):. PubMed ID: 30327442
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Anti-HIV agents that selectively target retroviral nucleocapsid protein zinc fingers without affecting cellular zinc finger proteins.
    Huang M; Maynard A; Turpin JA; Graham L; Janini GM; Covell DG; Rice WG
    J Med Chem; 1998 Apr; 41(9):1371-81. PubMed ID: 9554870
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A mimic of HIV-1 nucleocapsid protein impairs reverse transcription and displays antiviral activity.
    Druillennec S; Dong CZ; Escaich S; Gresh N; Bousseau A; Roques BP; Fournié-Zaluski MC
    Proc Natl Acad Sci U S A; 1999 Apr; 96(9):4886-91. PubMed ID: 10220388
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Potential drug targets on the HIV-1 envelope glycoproteins, gp120 and gp41.
    Huang L; Zhang L; Chen CH
    Curr Pharm Des; 2003; 9(18):1453-62. PubMed ID: 12769725
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Fullerene Derivatives Strongly Inhibit HIV-1 Replication by Affecting Virus Maturation without Impairing Protease Activity.
    Martinez ZS; Castro E; Seong CS; Cerón MR; Echegoyen L; Llano M
    Antimicrob Agents Chemother; 2016 Oct; 60(10):5731-41. PubMed ID: 27431232
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A synthetic HIV-1 protease inhibitor with antiviral activity arrests HIV-like particle maturation.
    Dis Markers; 1990; 8(3):162-3. PubMed ID: 2125537
    [No Abstract]   [Full Text] [Related]  

  • 60. HIV-1 Matrix Trimerization-Impaired Mutants Are Rescued by Matrix Substitutions That Enhance Envelope Glycoprotein Incorporation.
    Tedbury PR; Novikova M; Alfadhli A; Hikichi Y; Kagiampakis I; KewalRamani VN; Barklis E; Freed EO
    J Virol; 2019 Dec; 94(1):. PubMed ID: 31619553
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.